10-Q: BillionToOne Reports Strong Q2 2026 Growth

BillionToOne, Inc. announced significant revenue growth of 64% year-over-year for Q2 2026, driven by increased test volumes and higher average selling prices, alongside a substantial increase in cash and cash equivalents.

Summary

• BillionToOne reported a 64% increase in revenue for the three months ended June 30, 2026, reaching $109.4 million, compared to $66.6 million in the prior year period.
• Gross profit surged by 77% to $77.1 million, with gross margin improving to 70% from 65% in the same period last year.
• Net income for the quarter was $8.1 million, a significant turnaround from a net loss of $0.2 million in Q2 2025.
• Cash and cash equivalents increased to $548.6 million as of June 30, 2026, up from $496.0 million at the end of 2025.
• The company experienced a 40% increase in delivered and billable test volume year-over-year.
• Operating expenses increased, with R&D up 47% and SG&A up 63%, reflecting investments in growth and operations.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive report, with strong revenue growth, improved gross margins, and a significant increase in cash reserves, indicating robust operational performance and financial health.

Positives

• Revenue increased by 64.4% to $109.4 million for the three months ended June 30, 2026, compared to $66.6 million in the prior year.
• Gross profit increased by 77.4% to $77.1 million, with gross margin improving to 70% from 65%.
• Net income turned positive at $8.1 million for the quarter, compared to a net loss of $0.2 million in the prior year.
• Cash and cash equivalents grew to $548.6 million as of June 30, 2026.
• Overall ASP increased by 21% for the quarter, driven by expanded payor contracts and the company's proprietary PLA code.
• Test volume increased by 35% for the quarter, indicating strong market adoption.
• The company is actively expanding its laboratory capacity with new facilities planned in Austin, Texas and Union City, California.

Negatives

• Selling, general and administrative expenses increased by 62.8% to $54.3 million, driven by increased headcount and operational costs.
• Research and development expenses increased by 47.3% to $17.3 million, reflecting ongoing investment in product development.
• The company reported material weaknesses in its internal control over financial reporting, specifically related to control environment, financial instruments, and user access controls, which remain unremediated.
• The company's long-term debt increased to $91.0 million as of June 30, 2026.

Risks

• Illumina, Inc. filed a lawsuit alleging infringement of U.S. Patent Nos. 10,612,096, 12,139,760 and 12,435,373 by BillionToOne's UNITY test.
• The company's success depends on maintaining and expanding market acceptance and achieving commercial success in its prenatal and oncology product lines.
• Payor coverage, contracting, and reimbursement remain critical, as third-party reimbursement constitutes over 90% of revenue.
• The company is subject to regulatory and enforcement actions by federal and state governments, which could result in penalties.
• The company's ability to remediate material weaknesses in internal control over financial reporting is ongoing and could impact future reporting.
• Future capital requirements may necessitate seeking additional financing, which may not be available on favorable terms.

Future Outlook

The company expects revenue to increase over time due to expanded sales efforts, new product introductions, and increased payor contracts. Investments in R&D are expected to continue, with R&D costs increasing in absolute dollars but moderately declining as a percentage of revenue. SG&A expenses are also expected to increase in absolute dollars due to growth in sales and marketing personnel and public company compliance costs. The company anticipates occupying new laboratory facilities in Austin, Texas in 2027 and Union City, California in 2027, which are expected to significantly increase testing capacity.

Management Comments

• BillionToOne is transforming healthcare by redefining molecular diagnostics with its single-molecule next-generation sequencing (smNGS) platform.
• The company has processed over one and a half million smNGS-based tests to date, with over 42% processed in the last 12 months.
• UNITY is the first single-gene non-invasive prenatal test (sgNIPT) that uses cfDNA to provide fetal risk assessment for recessive conditions without requiring a paternal sample or invasive procedures.
• The company is developing a tissue-free, pan-cancer MRD test, expected to be commercially available in Q4 2026.
• The company has invested in building a high-performing, specialized team dedicated to reimbursement, including integrating AI for efficiency improvements.
• The company expects to maintain significant levels of investment in research and development to develop new assays and expand testing capabilities.

Industry Context

StockSavvy.ai notes that BillionToOne's performance aligns with the growing demand for advanced molecular diagnostics, particularly in prenatal and oncology screening. The company's focus on single-molecule sensitivity and AI integration positions it well within a competitive landscape that increasingly values precision and early detection.

Comparison to Industry Standards

• BillionToOne's UNITY Fetal Risk Screen, with the addition of a 130-gene panel, is positioned as the largest single-gene NIPT panel available.
• The Northstar Select test claims to detect over 50% more actionable solid tumor mutations than conventional liquid biopsies.
• Northstar Response is highlighted as the only methylation-based assay that quantifies tumor burden at the single molecule level without requiring a tissue biopsy.
• The company's smNGS platform achieves single-molecule sensitivity, a capability that addresses a fundamental limitation in detecting sparse but clinically crucial disease signals in cfDNA.

Legal Proceedings

• Illumina, Inc. v. BillionToOne, Inc.: Illumina filed a lawsuit on May 7, 2026, alleging that BillionToOne's UNITY test infringes U.S. Patent Nos. 10,612,096, 12,139,760 and 12,435,373. BillionToOne maintains the allegations are without merit and is defending itself.

Related Party Transactions

• In June 2025, the Company granted stock options to certain founders and executive officers under the 2018 Plan, approved by the Board of Directors. No material related party transactions during the three and six months ended June 30, 2026.

Stakeholder Impact

• Shareholders: Positive impact from strong revenue growth, improved profitability, and increased cash reserves, though ongoing material weaknesses in internal controls warrant attention.
• Customers (Physicians/Healthcare Providers): Continued access to advanced diagnostic tools for prenatal and oncology care, with potential for improved patient outcomes.
• Payors: Increased engagement through expanded contracts and proprietary codes, influencing reimbursement strategies.
• Employees: Continued investment in R&D and expansion may lead to growth opportunities, alongside ongoing efforts to strengthen financial reporting controls.

Next Steps

• Continue to expand sales efforts and introduce new products.
• Increase payor contracts and pursue favorable reimbursement decisions.
• Invest in research and development for new molecular diagnostic assays and enhancements.
• Develop and commercialize new testing methodologies and platforms.
• Expand laboratory capacity with new facilities in Austin, Texas and Union City, California.
• Focus on MRD detection with a tissue-free, pan-cancer MRD test expected in Q4 2026.

Key Dates

Recommendation

The company demonstrates strong operational performance with significant revenue growth and improved profitability, alongside a robust cash position. However, the ongoing material weaknesses in internal controls over financial reporting and the pending patent litigation with Illumina introduce notable risks that warrant a cautious approach. Therefore, a 'hold' recommendation is appropriate pending further clarity on these issues.

Keywords

molecular diagnostics, prenatal testing, oncology diagnostics, liquid biopsy, single-molecule sequencing, NIPT, cfDNA, revenue growth